Legend Biotech Stock
Legend Biotech Corporation
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Alan S. Bash
- Employees
- 3,200
- Market cap
- $3.4 B
- IPO
- 05/06/2020
Legend Biotech Corporation is a biopharmaceutical company operating in the healthcare sector that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications. Founded in 2014, the company is headquartered in Somerset, New Jersey, and conducts its business across the…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Legend Biotech stock: price history
1D
-6.7%
1W
-0.8%
1M
+8.7%
6M
-12.7%
YTD
-15.0%
1Y
-42.9%
2Y
-58.0%
5Y
-64.4%
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~7% stronger price swings than usual
Ask the agents about Legend Biotech
Analyst assessment of Legend Biotech
PRICE TARGET LOW
US$40.00
CONSENSUS
US$61.00
MEDIAN
US$65.00
PRICE TARGET HIGH
US$78.00
0
STRONG BUY
14
BUY
6
HOLD
0
SELL
0
STRONG SELL
20
TOTAL · Buy
As of: 13/10/2026
Legend Biotech stock metrics
P/E
-36.96
P/B
2.81
EV/EBITDA
1,470.35
RETURN ON EQUITY
2.7%
NET MARGIN
8.6%
DEBT/EQUITY
0.23
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
96.3%
FLOAT SHARES
178,182,956
AVG. DAILY VOLUME (30D)
2,284,983
Insider transactions (SEC)
Sanders Corazon (Corsee) D.
Sanders Corazon (Corsee) D.
Heyman Tomas J.
Ji Darren Xiaohui
Casey Patrick John
Institutional holders
Comparable stocks
Frequently asked questions about Legend Biotech stock
What does Legend Biotech do?
Legend Biotech Corporation is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Alan S. Bash, the company employs around 3,200 people.
The IPO was on 05/06/2020; the stock trades on NASDAQ under the ticker LEGN.
What do analysts say about Legend Biotech stock?
20 analysts rate the stock, the consensus is Buy (as of 13/10/2026).
The average price target is US$61.00, ranging from US$40.00 to US$78.00, with a median of US$65.00.
This is an external assessment, not a statement by Market Jury.
When does Legend Biotech report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 7% stronger than usual.
Does Legend Biotech pay a dividend?
No, Legend Biotech currently does not pay a dividend.
Which stocks are comparable to Legend Biotech?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Legend Biotech stock analyzed?
Clicking "Analyze stock" lets five strategies assess Legend Biotech against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.